Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

(2019) John J.V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

(2019) Emelia J. Benjamin et al.   CIRCULATION

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

(2017) James L. Januzzi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

(2015) Silvio E Inzucchi et al.   Diabetes & Vascular Disease Research

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Forecasting the Impact of Heart Failure in the United States

(2013) Paul A. Heidenreich et al.   Circulation-Heart Failure

Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure

(2011) Kathryn E. Flynn et al.   AMERICAN HEART JOURNAL

Editorial Assessing renal function – searching for the perfect marker continues!

(2011) Devaki R. Nair et al.   Archives of Medical Science

Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study

(2011) Inger Ekman et al.   EUROPEAN HEART JOURNAL

Epidemiology and risk profile of heart failure

(2010) Anh L. Bui et al.   Nature Reviews Cardiology

N-Terminal Pro–B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure

(2009) John G. Lainchbury et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Only Large Reductions in Concentrations of Natriuretic Peptides (BNP and NT-proBNP) Are Associated with Improved Outcome in Ambulatory Patients with Chronic Heart Failure

(2008) W. L. Miller et al.   CLINICAL CHEMISTRY